These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8775390)

  • 1. Hormone-containing cosmetics may cause signs of early sexual development.
    Zimmerman PA; Francis GL; Poth M
    Mil Med; 1995 Dec; 160(12):628-30. PubMed ID: 8775390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premature sexual development in children following the use of estrogen- or placenta-containing hair products.
    Tiwary CM
    Clin Pediatr (Phila); 1998 Dec; 37(12):733-9. PubMed ID: 9864648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of unintentional exposure of children to compounded transdermal sex hormone therapy.
    Franklin SL
    Pediatr Endocrinol Rev; 2011 Mar; 8(3):208-12. PubMed ID: 21525797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone-containing hair product use in prepubertal children.
    Li ST; Lozano P; Grossman DC; Graham E
    Arch Pediatr Adolesc Med; 2002 Jan; 156(1):85-6. PubMed ID: 11772198
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in the management of sexual precocity in girls.
    Schriock EA; Martin MC
    Curr Opin Obstet Gynecol; 1991 Dec; 3(6):813-9. PubMed ID: 1818719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Precocious puberty and breast feminization possibly due to hair growth agent containing diethylstilbestrol].
    Takehiro A; Oka S; Hikita Y; Nakagawa Y; Igarashi Y
    Horumon To Rinsho; 1983 Jun; 31 Suppl():54-6. PubMed ID: 6616921
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogens in cosmetics.
    Med Lett Drugs Ther; 1985 Jun; 27(690):54-5. PubMed ID: 4000061
    [No Abstract]   [Full Text] [Related]  

  • 9. Disorders of Puberty: An Approach to Diagnosis and Management.
    Klein DA; Emerick JE; Sylvester JE; Vogt KS
    Am Fam Physician; 2017 Nov; 96(9):590-599. PubMed ID: 29094880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.
    Lazar L; Padoa A; Phillip M
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3483-9. PubMed ID: 17579199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk.
    Donovan M; Tiwary CM; Axelrod D; Sasco AJ; Jones L; Hajek R; Sauber E; Kuo J; Davis DL
    Med Hypotheses; 2007; 68(4):756-66. PubMed ID: 17127015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound assessment of breast development: distinction between premature thelarche and precocious puberty.
    Youn I; Park SH; Lim IS; Kim SJ
    AJR Am J Roentgenol; 2015 Mar; 204(3):620-4. PubMed ID: 25714294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult height in precocious puberty after long-term treatment with deslorelin.
    Oerter KE; Manasco P; Barnes KM; Jones J; Hill S; Cutler GB
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1235-40. PubMed ID: 1955504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
    Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
    Sørensen K; Andersson AM; Skakkebaek NE; Juul A
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Puberty without gonadotropins. A unique mechanism of sexual development.
    Wierman ME; Beardsworth DE; Mansfield MJ; Badger TM; Crawford JD; Crigler JF; Bode HH; Loughlin JS; Kushner DC; Scully RE
    N Engl J Med; 1985 Jan; 312(2):65-72. PubMed ID: 3917301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual precocity in a 2-year-old boy caused by indirect exposure to testosterone cream.
    Stephen MD; Jehaimi CT; Brosnan PG; Yafi M
    Endocr Pract; 2008 Nov; 14(8):1027-30. PubMed ID: 19095605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.
    Paul D; Conte FA; Grumbach MM; Kaplan SL
    J Clin Endocrinol Metab; 1995 Feb; 80(2):546-51. PubMed ID: 7852518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.